Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05521438 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

StatusActive, Not Recruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Dec 31, 2025 to Dec 30, 2025
    • Study completion date: Dec 31, 2025 to Dec 31, 2026
    v6
  2. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 5 of 5 sites
    v5
  3. Primary and study completion dates: Jan 31, 2025 to Dec 31, 2025v4
  4. Enrollment target: 18 to 30v3 Show 5 more changesShow less
    • Study sites: 2 to 5
    • Primary and study completion dates: Dec 2024 to Jan 31, 2025
    • Interventions: QRX003-2% Lotion (Drug), QRX003-4% Lotion (Drug), Vehicle (Drug) to QRX003-2% Lotion (Drug), QRX003-4% Lotion BID (Drug), QRX003-4% Lotion QAM (Drug), Vehicle (Drug)
    • Eligibility criteria revised
    • Study arms: 3 to 4
  5. Primary and study completion dates: Jun 2023 to Dec 2024v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study has been designed to determine the safety, tolerability and efficacy of QRX003 lotion 2%, 4% QAM or 4% BID in subjects with Netherton Syndrome (NS) in comparison to vehicle
Trial Details
NCT Number NCT05521438
Lead Sponsor Quoin Pharmaceuticals
Conditions
(from sponsor)		 Netherton Syndrome
Related terms Netherton Syndrome
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov